Aditya Bardia, MD, MPH shares his approach to assessing breast cancer recurrence risk and monitoring patients during and after treatment.
Post-Conference Perspectives: Breast Cancer Recurrence Monitoring by ctDNA
A breast cancer expert provides a brief overview of clinical evidence supporting the use of ctDNA to detect recurrence.
Dr. Bardia reviews data from the ASCO 2022 Annual Meeting, focusing on serial postoperative ctDNA monitoring for breast cancer recurrence.
Clinical pearls addressing the current and potential future applications of ctDNA in breast cancer monitoring strategies.
Experienced clinician shares insight on potential challenges in the use of ctDNA monitoring.
Dr. Bardia discusses promising biomarkers and strategies for helping assess risk and detect recurrence in breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5